Xiaoping Jin

3.5k total citations · 3 hit papers
70 papers, 2.7k citations indexed

About

Xiaoping Jin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Xiaoping Jin has authored 70 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 17 papers in Surgery. Recurrent topics in Xiaoping Jin's work include Cancer Immunotherapy and Biomarkers (34 papers), Bladder and Urothelial Cancer Treatments (14 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Xiaoping Jin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (34 papers), Bladder and Urothelial Cancer Treatments (14 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Xiaoping Jin collaborates with scholars based in United States, China and United Kingdom. Xiaoping Jin's co-authors include Ashok Gupta, Bradley P. Carlin, Sudipto Banerjee, Christophe Massard, Peter H. O’Donnell, Yong Ben, Marlon C. Rebelatto, Joyce Antal, John A. Blake-Haskins and Neil H. Segal and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Xiaoping Jin

67 papers receiving 2.6k citations

Hit Papers

Efficacy and Safety of Du... 2016 2026 2019 2022 2017 2016 2025 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
    2017 664 citations Peter H. O’Donnell, Christophe Massard et al. profile →
  2. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
    2016 661 citations Christophe Massard, Michael S. Gordon et al. Journal of Clinical Oncology profile →
  3. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
    2025 16 citations Yongmei Yin, Ying Fan et al. Nature Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Xiaoping Jin 1.8k 961 564 527 290 70 2.7k
Steven J. Lemery 1.8k 1.0× 482 0.5× 613 1.1× 852 1.6× 545 1.9× 65 3.3k
Ian M. Waxman 2.3k 1.2× 269 0.3× 717 1.3× 993 1.9× 434 1.5× 35 2.8k
Alice Chen 1.3k 0.7× 241 0.3× 346 0.6× 624 1.2× 156 0.5× 14 1.8k
Lola A. Fashoyin‐Aje 1.1k 0.6× 221 0.2× 264 0.5× 450 0.9× 295 1.0× 69 1.9k
D. Schultz 1.1k 0.6× 297 0.3× 425 0.8× 780 1.5× 383 1.3× 28 2.3k
Michael H. Veeder 1.7k 0.9× 488 0.5× 134 0.2× 483 0.9× 250 0.9× 24 2.3k
G. Pentheroudakis 1.3k 0.7× 331 0.3× 151 0.3× 411 0.8× 500 1.7× 33 2.2k
Lisa Sengeløv 1.4k 0.8× 2.1k 2.2× 303 0.5× 1.1k 2.0× 581 2.0× 45 3.5k
Hyunseok Kang 2.0k 1.1× 1000 1.0× 336 0.6× 889 1.7× 772 2.7× 102 3.4k
Christine K. Gause 1.6k 0.9× 336 0.3× 613 1.1× 523 1.0× 379 1.3× 38 2.0k

Countries citing papers authored by Xiaoping Jin

Since Specialization
Citations

This map shows the geographic impact of Xiaoping Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoping Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoping Jin more than expected).

Fields of papers citing papers by Xiaoping Jin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoping Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoping Jin. The network helps show where Xiaoping Jin may publish in the future.

Co-authorship network of co-authors of Xiaoping Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoping Jin. A scholar is included among the top collaborators of Xiaoping Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoping Jin. Xiaoping Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yin, Yongmei, Ying Fan, Xiaojia Wang, et al.. (2025). Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nature Medicine. 31(6). 1969–1975. 16 indexed citations breakdown →
2.
3.
Fang, Wenfeng, Ying Cheng, Zhendong Chen, et al.. (2024). Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study. Cancer Research. 84(7_Supplement). CT247–CT247. 12 indexed citations
4.
Zheng, Yulong, Anna Rachelle Mislang, Jermaine Coward, et al.. (2022). Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. Cancer Immunology Immunotherapy. 71(10). 2371–2379. 14 indexed citations
5.
Mai, Hai‐Qiang, Shaojun Lin, Dongping Chen, et al.. (2021). 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy. Regular and Young Investigator Award Abstracts. A466–A466. 14 indexed citations
6.
Zając, M, Jiabu Ye, Pralay Mukhopadhyay, et al.. (2020). Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. PLoS ONE. 15(4). e0231936–e0231936. 16 indexed citations
7.
8.
Markman, Ben, Ben Tran, Hui Gan, et al.. (2019). A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 7. 3 indexed citations
9.
Sridhar, Sriram, Luis Paz‐Ares, Hao Liu, et al.. (2019). Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. Clinical Lung Cancer. 20(6). e601–e608. 37 indexed citations
10.
Zając, Magdalena, Anne-Marie Boothman, Yong Ben, et al.. (2018). Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. Archives of Pathology & Laboratory Medicine. 143(6). 722–731. 18 indexed citations
11.
Jin, Xiaoping, Kenji Nakamaru, Matthias Schneider, et al.. (2017). Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non–Small Cell Lung Cancer Tissue. Biomarker Insights. 12. 2138186625–2138186625. 4 indexed citations
12.
Massard, Christophe, Michael S. Gordon, Sunil Sharma, et al.. (2016). Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. Journal of Clinical Oncology. 34(26). 3119–3125. 661 indexed citations breakdown →
13.
Rebelatto, Marlon C., Anita Midha, Amita Mistry, et al.. (2016). Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagnostic Pathology. 11(1). 95–95. 135 indexed citations
14.
Wang, Xinling, et al.. (2015). [Changes of thyroid function, thyroid antibodies and urinary iodine among permanent residents of Urumqi in Xinjiang].. PubMed. 36(8). 811–4. 1 indexed citations
15.
Guo, Yanying, et al.. (2015). Low Serum Vitamin D Is Associated with Anti-Thyroid-Globulin Antibody in Female Individuals. International Journal of Endocrinology. 2015. 1–6. 33 indexed citations
16.
17.
Rosenstock, Julio, Vivian Fonseca, W. Timothy Garvey, et al.. (2010). Initial Combination Therapy with Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals Min Early Type 2 Diabetes. Endocrine Practice. 16(4). 629–640. 31 indexed citations
18.
Handelsman, Yehuda, Ronald Goldberg, W. Timothy Garvey, et al.. (2010). Colesevelam Hydrochloride to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study. Endocrine Practice. 16(4). 617–628. 31 indexed citations
19.
Jin, Xiaoping & Bradley P. Carlin. (2005). Multivariate Parametric Spatiotemporal Models for County Level Breast Cancer Survival Data. Lifetime Data Analysis. 11(1). 5–27. 15 indexed citations
20.
Jin, Xiaoping, Bradley P. Carlin, & Sudipto Banerjee. (2005). Generalized Hierarchical Multivariate CAR Models for Areal Data. Biometrics. 61(4). 950–961. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven J. Lemery Breakdown of academic impact, for papers by Ian M. Waxman Breakdown of academic impact, for papers by Alice Chen Breakdown of academic impact, for papers by Lola A. Fashoyin‐Aje Breakdown of academic impact, for papers by D. Schultz Breakdown of academic impact, for papers by Michael H. Veeder Breakdown of academic impact, for papers by G. Pentheroudakis Breakdown of academic impact, for papers by Lisa Sengeløv Breakdown of academic impact, for papers by Hyunseok Kang Breakdown of academic impact, for papers by Christine K. Gause
Rankless by CCL
2026